Lucence Diagnostics

Executive Summary

Lucence Diagnostics is a Singapore-based precision oncology company specializing in ultra-sensitive liquid biopsy and multi-cancer early detection tests. Founded in 2016, the company leverages its proprietary AmpliMARK™ platform to analyze circulating tumor DNA (ctDNA) and RNA (ctRNA) for therapy selection and disease monitoring. Its product portfolio includes LiquidHALLMARK (comprehensive genomic profiling), LucenceINSIGHT (minimal residual disease detection), and LucenceLONGEVITY (early cancer screening), targeting oncology as well as broader age-related diseases. With $30 million in estimated funding and a team of 200-500 employees, Lucence has established a commercial presence in Asia and is poised to expand globally. Lucence operates in the rapidly growing liquid biopsy market, which is projected to exceed $10 billion by 2030. The company's multi-cancer early detection test, LucenceLONGEVITY, offers potential for population screening, while its AmpliMARK technology differentiates it with high sensitivity and the ability to detect both ctDNA and ctRNA. Key near-term catalysts include potential regulatory approvals (e.g., US FDA clearance for LiquidHALLMARK or CE-IVDR certification), new clinical data validating its early detection test, and strategic partnerships with healthcare providers or pharmaceutical companies. Given its commercial traction and novel platform, Lucence is well-positioned to capture market share, though competition from established players like Guardant Health and Exact Sciences remains a risk.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for LiquidHALLMARK comprehensive liquid biopsy test60% success
• Q2 2026Publication of pivotal clinical data for LucenceLONGEVITY multi-cancer early detection70% success
• Q3 2026Major hospital network or pharmaceutical partnership for distribution in Asia or US65% success